Pharmaceutical

J&J signs Stelara biosimilar settlement deal with Formycon and Fresenius

The deal sets the biosimilar’s potential US launch date to no later than April 2025, following two agreements signed earlier this year.

Aug 8, 2023 - 20:00
J&J signs Stelara biosimilar settlement deal with Formycon and Fresenius
The deal sets the biosimilar’s potential US launch date to no later than April 2025, following two agreements signed earlier this year.
Read the original article

Tags:

Previous Article

Astellas invests $50m in Poseida’s CAR-T cell therapy

Next Article

Arcus and Gilead terminate development for etrumadenant in prostate cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA’s Peter Marks seems inclined to grant full approval to Sarepta’s Duchenne gene therapy

STAT+: FDA’s Peter Marks seems inclined to grant full a...

Jan 10, 2024

STAT+: How the FDA’s pandemic flexibilities boosted mental health apps — and what happens now

STAT+: How the FDA’s pandemic flexibilities boosted men...

May 11, 2023

STAT+: An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

STAT+: An exit interview with Bristol Myers Squibb CEO ...

Oct 30, 2023